Antibacterial action of nitric oxide-releasing chitosan oligosaccharides against Pseudomonas aeruginosa under aerobic and anaerobic conditions

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6506-6513

  Reighard, Katelyn P ^a   Schoenfisch, Mark H ^a  

^a The University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHITOSAN DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; OLIGOSACCHARIDE; OXYGEN; TOBRAMYCIN; AZO COMPOUND; CHITOSAN; DIAZENIUMDIOLATE; GLYCOSAMINOGLYCAN; MUCOID EXOPOLYSACCHARIDE (P AERUGINOSA);

AEROBIC CELL CULTURE; ANAEROBIC CELL CULTURE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOFILM; BIOSYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; AEROBIC METABOLISM; ANAEROBIC GROWTH; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

AEROBIOSIS; ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; AZO COMPOUNDS; BIOFILMS; CHITOSAN; GLYCOSAMINOGLYCANS; MICROBIAL SENSITIVITY TESTS; NITRIC OXIDE; NITRIC OXIDE DONORS; OXYGEN; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84942279502     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01208-15     Document Type: Article

References (61)

1. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2:1051-1060. http://dx.doi.org/10.1016/S1286-4579(00)01259-4.
2. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560-578. http://dx.doi.org/10.1111/j.1469-0691.2007.01681.x.
3. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2:65. http://dx.doi.org/10.3389/fmicb.2011.00065.
4. Poole K. 2002. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 3:77-98. http://dx.doi.org/10.2174/1389201023378454.
5. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419-426. http://dx.doi.org/10.1016/j.tim.2011.04.005.
6. Stewart PS, William Costerton J. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
7. Stewart PS. 2002. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107-113. http://dx.doi.org/10.1078/1438-4221-00196.
8. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 10:841-851. http://dx.doi.org/10.1038/nrmicro2907.
9. Xu KD, Stewart PS, Xia F, Huang C-T, McFeters GA. 1998. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microbiol 64:4035-4039.
10. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Sun Yoon S, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ. 2002. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 54:1425-1443. http://dx.doi.org/10.1016/S0169-409X(02)00152-7.
11. Schlessinger D. 1988. Failure of aminoglycoside antibiotics to kill anaerobic, low-pH, and resistant cultures. Clin Microbiol Rev 1:54-59.
12. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. 2006. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 188:7344-7353. http://dx.doi.org/10.1128/JB.00779-06.
13. Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S. 2009. Nitric oxide-mediated dispersal in single-and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol 2:370-378. http://dx.doi.org/10.1111/j.1751-7915.2009.00098.x.
14. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. 2009. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 30:2782-2789. http://dx.doi.org/10.1016/j.biomaterials.2009.01.052.
15. Lu Y, Slomberg DL, Schoenfisch MH. 2014. Nitric oxide-releasing chitosan oligosaccharides as antibacterial agents. Biomaterials 35:1716-1724. http://dx.doi.org/10.1016/j.biomaterials.2013.11.015.
16. Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Döring G, Mehta S. 2013. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros 12:817-820. http://dx.doi.org/10.1016/j.jcf.2013.01.008.
17. Webert KE, Vanderzwan J, Duggan M, Scott JA, McCormack DG, Lewis JF, Mehta S. 2000. Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit Care Med 28:2397-2405.
18. Möller MN, Li Q, Lancaster JR, Denicola A. 2007. Acceleration of nitric oxide autoxidation and nitrosation by membranes. IUBMB Life 59:243-248. http://dx.doi.org/10.1080/15216540701311147.
19. Fang FC. 1997. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 99:2818.
20. Spiro S. 2007. Regulators of bacterial responses to nitric oxide. FEMS Microbiol Rev 31:193-211. http://dx.doi.org/10.1111/j.1574-6976.2006.00061.x.
21. Carpenter AW, Schoenfisch MH. 2012. Nitric oxide release. Part II. Therapeutic applications. Chem Soc Rev 41:3742-3752. http://dx.doi.org/10.1039/c2cs15273h.
22. Ren B, Zhang N, Yang J, Ding H. 2008. Nitric oxide-induced bacteriostasis and modification of iron-sulphur proteins in Escherichia coli. Mol Microbiol 70:953-964. http://dx.doi.org/10.1111/j.1365-2958.2008.06464.x.
23. Johnson DC, Dean DR, Smith AD, Johnson MK. 2005. Structure, function, and formation of biological iron-sulfur clusters. Annu Rev Biochem 74:247-281. http://dx.doi.org/10.1146/annurev.biochem.74.082803.133518.
24. Loscalzo J, Welch G. 1995. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87-104. http://dx.doi.org/10.1016/S0033-0620(05)80001-5.
25. Samama CM, Diaby M, Fellahi J-L, Mdhafar A, Eyraud D, Arock M, Guillosson J-J, Coriat P, Rouby J-J. 1995. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 83:56-65. http://dx.doi.org/10.1097/00000542-199507000-00007.
26. Ferrari CKB, França EL, Honorio-França AC. 2009. Nitric oxide, health and disease. J Appl Biomed 7:163-173.
27. Riccio DA, Schoenfisch MH. 2012. Nitric oxide release. Part I. Macromolecular scaffolds. Chem Soc Rev 41:3731-3741. http://dx.doi.org/10.1039/c2cs15272j.
28. Seabra AB, Justo GZ, Haddad PS. 28 January 2015. State of the art, challenges and perspectives in the design of nitric oxide-releasing polymeric nanomaterials for biomedical applications. Biotechnol Adv S0734-9750(15)00018-X. http://dx.doi.org/10.1016/j.biotechadv.2015.01.005.
29. 2-Protected diazeniumdiolate-modified silica nanoparticles for extended nitric oxide release from dental composites. Biomater Sci 1:456-459. http://dx.doi.org/10.1039/c3bm00153a.
30. Shin JH, Metzger SK, Schoenfisch MH. 2007. Synthesis of nitric oxide-releasing silica nanoparticles. J Am Chem Soc 129:4612-4619. http://dx.doi.org/10.1021/ja0674338.
31. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. 2010. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 7:775-785. http://dx.doi.org/10.1021/mp9002865.
32. Lu Y, Slomberg DL, Shah A, Schoenfisch MH. 2013. Nitric oxide-releasing amphiphilic poly(amidoamine) (PAMAM) dendrimers as antibacterial agents. Biomacromolecules 14:3589-3598. http://dx.doi.org/10.1021/bm400961r.
33. Sun B, Slomberg DL, Chudasama SL, Lu Y, Schoenfisch MH. 2012. Nitric oxide-releasing dendrimers as antibacterial agents. Biomacromolecules 13:3343-3354. http://dx.doi.org/10.1021/bm301109c.
34. Worley BV, Slomberg DL, Schoenfisch MH. 2014. Nitric oxide-releasing quaternary ammonium-modified poly(amidoamine) dendrimers as dual action antibacterial agents. Bioconjug Chem 25:918-927. http://dx.doi.org/10.1021/bc5000719.
35. Lu Y, Sun B, Li C, Schoenfisch MH. 2011. Structurally diverse nitric oxide-releasing poly(propylene imine) dendrimers. Chem Mater 23:4227-4233. http://dx.doi.org/10.1021/cm201628z.
36. Stasko NA, Schoenfisch MH. 2006. Dendrimers as a scaffold for nitric oxide release. J Am Chem Soc 128:8265-8271. http://dx.doi.org/10.1021/ja060875z.
37. Carpenter AW, Slomberg DL, Rao KS, Schoenfisch MH. 2011. Influence of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles. ACS Nano 5:7235-7244. http://dx.doi.org/10.1021/nn202054f.
38. Carpenter AW, Worley BV, Slomberg DL, Schoenfisch MH. 2012. Dual action antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica nanoparticles. Biomacromolecules 13:3334-3342. http://dx.doi.org/10.1021/bm301108x.
39. Slomberg DL, Lu Y, Broadnax AD, Hunter RA, Carpenter AW, Schoenfisch MH. 2013. Role of size and shape on biofilm eradication for nitric oxide-releasing silica nanoparticles. ACS Appl Mater Interfaces 5:9322-9329. http://dx.doi.org/10.1021/am402618w.
40. Grenha A, Al-Qadi S, Seijo B, Remuñán-López C. 2010. The potential of chitosan for pulmonary drug delivery. J Drug Deliv Sci Technol 20:33-43. http://dx.doi.org/10.1016/S1773-2247(10)50004-2.
41. Kean T, Thanou M. 2010. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62:3-11. http://dx.doi.org/10.1016/j.addr.2009.09.004.
42. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
43. Hunter RA, Storm WL, Coneski PN, Schoenfisch MH. 2013. Inaccuracies of nitric oxide measurement methods in biological media. Anal Chem 85:1957-1963. http://dx.doi.org/10.1021/ac303787p.
44. Breed RS, Dotterrer W. 1916. The number of colonies allowable on satisfactory agar plates. J Bacteriol 1:321.
45. Coneski PN, Schoenfisch MH. 2012. Nitric oxide release. Part III. Measurement and reporting. Chem Soc Rev 41:3753-3758. http://dx.doi.org/10.1039/c2cs15271a.
46. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317-325. http://dx.doi.org/10.1172/JCI0213870.
47. Wyckoff TJ, Thomas B, Hassett DJ, Wozniak DJ. 2002. Static growth of mucoid Pseudomonas aeruginosa selects for non-mucoid variants that have acquired flagellum-dependent motility. Microbiology 148:3423-3430.
48. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331. http://dx.doi.org/10.1023/A:1011929016601.
49. Jones ML, Ganopolsky JG, Labbé A, Wahl C, Prakash S. 2010. Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. Appl Microbiol Biotechnol 88:401-407. http://dx.doi.org/10.1007/s00253-010-2733-x.
50. Brunelli L, Crow JP, Beckman JS. 1995. The comparative toxicity of nitric oxide and peroxynitrite to Escherichia coli. Arch Biochem Biophys 316:327-334. http://dx.doi.org/10.1006/abbi.1995.1044.
51. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron SD. 2005. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43:5085-5090. http://dx.doi.org/10.1128/JCM.43.10.5085-5090.2005.
52. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. 2002. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40:4172-4179. http://dx.doi.org/10.1128/JCM.40.11.4172-4179.2002.
53. Donlan R. 2008. Biofilms on central venous catheters: is eradication possible? Curr Top Microbiol Immunol 322:133-161.
54. Cole SJ, Records AR, Orr MW, Linden SB, Lee VT. 2014. Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. Infect Immun 82:2048-2058. http://dx.doi.org/10.1128/IAI.01652-14.
55. Harrison-Balestra C, Cazzaniga AL, Davis SC, Mertz PM. 2003. A wound-isolated Pseudomonas aeruginosa grows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatol Surg 29:631-635.
56. Kennedy P, Brammah S, Wills E. 2010. Burns, biofilm and a new appraisal of burn wound sepsis. Burns 36:49-56. http://dx.doi.org/10.1016/j.burns.2009.02.017.
57. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5:1663-1674. http://dx.doi.org/10.2217/fmb.10.125.
58. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock RE, Parsek MR, Noah TL, Boucher RC, Hassett DJ. 2002. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 3:593-603. http://dx.doi.org/10.1016/S1534-5807(02)00295-2.
59. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR. 2001. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 183:5395-5401. http://dx.doi.org/10.1128/JB.183.18.5395-5401.2001.
60. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. 2004. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 48:2659-2664. http://dx.doi.org/10.1128/AAC.48.7.2659-2664.2004.
61. Field T, White A, Elborn J, Tunney M. 2005. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur J Clin Microbiol Infect Dis 24:677-687. http://dx.doi.org/10.1007/s10096-005-0031-9.